Malaysia approves additional indication for Astrazeneca’s Evusheld
Pharmaceutical Technology
APRIL 10, 2023
It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061).
Let's personalize your content